TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24763890

Group type: EXPERIMENTAL
Intervention: Topical cream containing 0.5% Aloe vera juice powder applied 3 times per day for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22495174

Group type: EXPERIMENTAL
Intervention: DRD1 genetic variants (rs11746641, rs2168631, rs11749035) in slow nicotine metabolizers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal nicotine metabolizers)
Number of subjects: 0
Study: 19504468

Group type: EXPERIMENTAL
Intervention: Herbal and mineral complex (HMC) - Astragalus membranaceus
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 17950564

Group type: EXPERIMENTAL
Intervention: Endovascular revision
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Open surgical revision
Number of subjects: 1404

Group type: COMPARATOR
Intervention: Control (not explicitly defined)
Number of subjects: 1404
Study: 16268392

Group type: EXPERIMENTAL
Intervention: Ranir Whitening Wraps (WW2) used twice a day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Crest Whitestrips Premium (WP2) used twice a day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ranir Whitening Wraps (WW1) used once a day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study: 12162472

Group type: EXPERIMENTAL
Intervention: 15-minute TEAS alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg morphine alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15-minute TEAS plus morphine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline plus no TEAS
Number of subjects: 20
Study: 9861593

Group type: EXPERIMENTAL
Intervention: 200 mg of magnesium (as MgO)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7635854

Group type: EXPERIMENTAL
Intervention: Clomipramine or Fluoxetine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 53
Study: 2694119

Group type: EXPERIMENTAL
Intervention: 0.0175 i.u..kg‐1 min‐1 calcitonin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.0350 i.u..kg‐1 min‐1 calcitonin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: calcitonin
Number of subjects: 7
Study: 665564

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Included ileum
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Nonfunctional jejunum
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Nonfunctional ileum
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Serum magnesium levels
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Serum total protein concentrations
Number of subjects: 101
Study: 31900174

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BASDAI50 responders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASAS40 responders
Number of subjects: 0
Study: 31685913

Group type: EXPERIMENTAL
Intervention: Modified aerobic training with a load on the lower limbs (MG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional aerobic training (CG)
Number of subjects: 40
Study: 26856247

Group type: EXPERIMENTAL
Intervention: Prednisone (PD) treatment over 4.3 years
Number of subjects: 520

Group type: COMPARATOR
Intervention: High-dose anti-metabolite treatment arm
Number of subjects: 520
Study: 25633090

Group type: EXPERIMENTAL
Intervention: Gallopamil
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23386641

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4800 IU daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Vitamin D3 800 IU daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Calcium supplements to maintain total calcium intake of 1200-1400 mg/d
Number of subjects: 110
Study: 20140470

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer cement restorations (single-surface)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer cement restorations (multiple-surface)
Number of subjects: 43
Study: 19586229

Group type: EXPERIMENTAL
Intervention: Oral methadone-naloxone in a 50:1 ratio
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intramuscular methadone-naloxone in a 50:1 ratio
Number of subjects: 15

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 15
Study: 17931936

Group type: EXPERIMENTAL
Intervention: 38% hydrogen peroxide exposure (A1-A4 and B1-B4)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Distilled water immersion (A5 and B5)
Number of subjects: 140
Study: 15818698

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12354601

Group type: EXPERIMENTAL
Intervention: TACE/PEI group (32 patients)
Number of subjects: 69

Group type: COMPARATOR
Intervention: TACE group (37 patients)
Number of subjects: 69
Study: 9443485

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone
Number of subjects: 66

Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 66
Study: 8006397

Group type: EXPERIMENTAL
Intervention: 4-week course of prednisolone followed by 2 weeks of no treatment and then a 12-week course of human lymphoblastoid interferon, 4 to 6 MU/m2 intramuscularly
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo given instead of prednisolone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4-week course of prednisolone followed by interferon
Number of subjects: 120
Study: 2920071

Group type: EXPERIMENTAL
Intervention: 1 g/kg of alcohol (12.5%, v/v)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study: 812362

Group type: EXPERIMENTAL
Intervention: Cephalosporins
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30207254

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 315
Study: 29241576

Group type: EXPERIMENTAL
Intervention: 1 × 300 mL plum juice
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3 × 100 mL plum juice
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 24
Study: 25487567

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg · kg(‐1) (Group D1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg · kg(‐1) (Group D2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 90
Study: 23924065

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 113

Group type: COMPARATOR
Intervention: Active comparison condition (health education)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 113
Study: 21539635

Group type: EXPERIMENTAL
Intervention: PVAI ablation
Number of subjects: 118

Group type: COMPARATOR
Intervention: CFE ablation
Number of subjects: 118

Group type: COMPARATOR
Intervention: CFE ablation alone
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: PVAI ablation alone
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: PVAI + CFE ablation
Number of subjects: 118
Study: 19532851

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study: 16214329

Group type: EXPERIMENTAL
Intervention: PUFA n-3 supplementation (3.6 g daily for 3 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (olive oil for 3 months)
Number of subjects: 24
Study: 15541061

Group type: EXPERIMENTAL
Intervention: STEP-BD sample
Number of subjects: 1000
Study: 11425671

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) therapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 9260214

Group type: EXPERIMENTAL
Intervention: Schwarz strain measles vaccine (SWMV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Edmoston-Zagreb strain measles vaccine (EZMV)
Number of subjects: 39
Study: 8033606

Group type: EXPERIMENTAL
Intervention: Retinoic acid (RA) alone at an oral dose of 45-60 mg/m2/d
Number of subjects: 107

Group type: COMPARATOR
Intervention: Combined therapy (RA and chemotherapy)
Number of subjects: 107

Group type: COMPARATOR
Intervention: RA as continuation therapy (Group A)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Chemotherapy (Group B)
Number of subjects: 107

Group type: COMPARATOR
Intervention: RA and chemotherapy alternately (Group C)
Number of subjects: 107
Study: 2451816

Group type: EXPERIMENTAL
Intervention: Flupirtine 100 mg capsules
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pentazocine 50 mg capsules
Number of subjects: 52
Study: 30141453

Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard cardioplegia (Group B)
Number of subjects: 60
Study: 27070985

Group type: EXPERIMENTAL
Intervention: Intensified work-related rehabilitation aftercare (IWORAC)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Conventional intensified rehabilitation aftercare (IRAC)
Number of subjects: 307
Study: 25156398

Group type: EXPERIMENTAL
Intervention: Attention training towards positive stimuli (ATP) combined with one-session treatment (OST)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Attention training control (ATC) combined with one-session treatment (OST)
Number of subjects: 37
Study: 23735669

Group type: EXPERIMENTAL
Intervention: Totally robotic Roux-en-Y gastric bypass (TR-RYGBP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional laparoscopic gastric bypass
Number of subjects: 200
Study: 20584565

Group type: EXPERIMENTAL
Intervention: 28 g acetogenic fibers (acacia gum and pectin)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (without acetogenic fibers)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fiber treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 21
Study: 18998824

Group type: EXPERIMENTAL
Intervention: More intensive BP-lowering group
Number of subjects: 1953

Group type: COMPARATOR
Intervention: Less intensive BP-lowering group
Number of subjects: 1953
Study: 15931646

Group type: EXPERIMENTAL
Intervention: 20.8 mg of sodium iron gluconate at the end of each dialysis session (Group A)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 62.5 mg of sodium iron gluconate only at the end of the 1st dialysis session of the week (Group B)
Number of subjects: 17
Study: 12514663

Group type: COMPARATOR
Intervention: Factor V Leiden mutation
Number of subjects: 395

Group type: COMPARATOR
Intervention: Beta-fibrinogen 448 A allele
Number of subjects: 395

Group type: COMPARATOR
Intervention: Prothrombin variant G20210A
Number of subjects: 395

Group type: COMPARATOR
Intervention: Factor V Leiden and hypertension interaction
Number of subjects: 395
Study: 10963500

Group type: EXPERIMENTAL
Intervention: Serum IGF-1 levels before RP (T0)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Serum IGF-1 levels after 6 months (T6)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 57
Study: 8784764

Group type: EXPERIMENTAL
Intervention: Exercise group (N = 17)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (N = 11)
Number of subjects: 28
Study: 1338083

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 2580171

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg orally (acute and fasting)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg orally (with concomitant food intake)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg orally (without concomitant food intake)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times a day for 4-5 weeks (chronic treatment)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg (twice daily)
Number of subjects: 9
Study: 31907076

Group type: EXPERIMENTAL
Intervention: Yi-Qi-Qing-Jie formula (YQF) combined with prednisolone and cyclophosphamide if necessary
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo-YQF combined with prednisolone and cyclophosphamide if necessary
Number of subjects: 60
Study: 30572928

Group type: EXPERIMENTAL
Intervention: Exercise intervention (3-month clinically supervised exercise programme)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 40
Study: 26400628

Group type: EXPERIMENTAL
Intervention: Topical antifungal treatment + oral antifungal
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical antifungal treatment + ICAMB + oral antifungal
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical antifungal treatment + drainage of hypopyon + ICAMB + oral antifungal
Number of subjects: 45
Study: 24902040

Group type: EXPERIMENTAL
Intervention: COMPAS delivered by experts only
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: COMPAS delivered by experts and peers
Number of subjects: 832

Group type: COMPARATOR
Intervention: Control group (not exposed to any intervention)
Number of subjects: 832
Study: 22341106

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FSG)
Number of subjects: 77447

Group type: COMPARATOR
Intervention: Colonoscopy instead of FSG
Number of subjects: 77447
Study: 21162931

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg oral midazolam (Group I)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (Group II)
Number of subjects: 48
Study: 18519835

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) consisting of seven standardized techniques for 20 minutes.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham therapy (light touch applied to the same anatomic regions for 20 minutes).
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: OMT group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 35
Study: 15741580

Group type: EXPERIMENTAL
Intervention: BIS-blinded group
Number of subjects: 100

Group type: COMPARATOR
Intervention: BIS-unblinded group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BIS-blinded group (single dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: BIS-unblinded group (single dose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BIS-blinded group (multiple doses)
Number of subjects: 100

Group type: COMPARATOR
Intervention: BIS-unblinded group (multiple doses)
Number of subjects: 100
Study: 12915670

Group type: COMPARATOR
Intervention: T and placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: T and letrozole
Number of subjects: 23
Study: 10566703

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.i.d. for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9012256

Group type: EXPERIMENTAL
Intervention: lerivon (L) for 1 month
Number of subjects: 50

Group type: COMPARATOR
Intervention: amitriptyline for 1 month
Number of subjects: 50

Group type: COMPARATOR
Intervention: relanium for 7 days
Number of subjects: 50
Study: 1768550

Group type: EXPERIMENTAL
Intervention: P6 acupuncture (50% of patients) for 5 min after induction of anaesthesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-acupuncture (50% of patients)
Number of subjects: 45
Study: 7334143

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pentobarbital
Number of subjects: 19

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 19
Study: 30652944

Group type: EXPERIMENTAL
Intervention: Balance training and foot and ankle mobilization (FAM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 28
Study: 31856749

Group type: EXPERIMENTAL
Intervention: RCA-two
Number of subjects: 52

Group type: COMPARATOR
Intervention: RCA-one
Number of subjects: 52

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 52
Study: 27870723

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 25434303

Group type: EXPERIMENTAL
Intervention: Matched unrelated hematopoietic cell transplantation (HCT) in first remission for patients with FLT3-ITD allelic ratio >0.8, poor day +15 marrow blast clearance, and adverse karyotypes; allogeneic HCT in high-risk AML performed in aplasia after induction chemotherapy
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Allogeneic HCT in aplasia
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Allogeneic HCT in remission
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Control arm: Sibling HCT in first complete remission for intermediate-risk or high-risk AML and matched unrelated HCT in complex karyotype AML
Number of subjects: 1179
Study: 23504636

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD with PegIFN/RBV (48 weeks)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD without lead-in (48 weeks)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg BID with lead-in (48 weeks)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD/LI (rerandomized to 48 weeks treatment)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD/LI, 240 mg QD, and 240 mg BID/LI (adverse events)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Faldaprevir 240 mg BID
Number of subjects: 290
Study: 21243318

Group type: EXPERIMENTAL
Intervention: 7.4% vaginal extract of the Brazilian pepper tree (Schinus terebinthifolius Raddi)
Number of subjects: 277

Group type: COMPARATOR
Intervention: 0.75% vaginal metronidazole
Number of subjects: 277
Study: 19136900

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40-80 mg daily)
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study: 17878480

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/d
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Vandetanib (limited-stage)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Vandetanib (extensive-stage)
Number of subjects: 107
Study: 15306112

Group type: EXPERIMENTAL
Intervention: Stent placement (group A)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No stent placement (group B)
Number of subjects: 104
Study: 12948282

Group type: EXPERIMENTAL
Intervention: α-tocopherol supplementation (50 mg/day for five to eight years)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: MnSOD ala/ala genotype
Number of subjects: 197
Study: 10641900

Group type: EXPERIMENTAL
Intervention: Small hole plate haptic lenses (Chiron C10UB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Large hole plate haptic lenses (Chiron C11UB)
Number of subjects: 50
Study: 7780491

Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF) 30 mg/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF)
Number of subjects: 20
Study: 2180388

Group type: EXPERIMENTAL
Intervention: Daily mud packs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Daily hot sulphur baths
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of mud packs and hot sulphur baths
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 7462801

Group type: EXPERIMENTAL
Intervention: cholestyramine (16g/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: clofibrate (2g/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: both clofibrate and cholestyramine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: cholestyramine (8g) administered 30 min prior to test
Number of subjects: 150
Study: 30713334

Group type: EXPERIMENTAL
Intervention: Cloud-based interactive management program
Number of subjects: 79

Group type: COMPARATOR
Intervention: Psoriasis nursing manual and regular follow-up (Control)
Number of subjects: 79
Study: 28591847

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (intervention group)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 544
Study: 25630944

Group type: EXPERIMENTAL
Intervention: RAP-eL (web-based e-learning platform) accessed over 4 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RAP-eL (web-based e-learning platform)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no access to RAP-eL)
Number of subjects: 80
Study: 23837192

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Larger decreases in MVPA throughout pregnancy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MVPA
Number of subjects: 24
Study: 20870205

Group type: EXPERIMENTAL
Intervention: Wire marking
Number of subjects: 53

Group type: COMPARATOR
Intervention: Methylene blue marking
Number of subjects: 53
Study: 19549996

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 6459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6459
Study: 17570410

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily from postoperative days 1 to 90
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sildenafil 50 mg per day as needed
Number of subjects: 50
Study: 15456678

Group type: EXPERIMENTAL
Intervention: Breast self-examination intervention
Number of subjects: 417

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 417
Study: 11199942

Group type: EXPERIMENTAL
Intervention: Olanzapine (daily doses ranging from 2.5 to 17.5 mg/day for up to 6 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Haloperidol (exact dosage and duration not specified)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (exact dosage and duration not specified)
Number of subjects: 84
Study: 9698979

Group type: EXPERIMENTAL
Intervention: High levels of fear of negative evaluation in women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other groups (not specified)
Number of subjects: 0